1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Legislation

Former FDA Cosmetics Director Weighs In On Senator Hatch's Draft FCSMA

 
• By Ryan Nelson

Under the draft FDA Cosmetic Safety and Modernization Act, a product could be deemed adulterated "regardless of whether it is known which particular substance or substances may render the cosmetic injurious." EAS Consulting Group's John Bailey offers his perspective on the provision and the overall bill in an exchange with the Rose Sheet.

John Bailey, former director of FDA's Office of Cosmetics and Colors turned industry regulatory consultant, says one thing in particular jumped out at him from the recently introduced FDA Cosmetic Safety and Modernization Act – the proposal to revise the federal definition of an "adulterated" cosmetic.

The draft bill, S. 2003, sponsored by Sen. Orrin Hatch, R-Utah, would amend the Federal Food, Drug and Cosmetic Act...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By Lauren Nardella

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.

Unanimous Support Across House Energy And Commerce To Reauthorize FDA’s OMUFA Program

 
• By Malcolm Spicer

Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

More from Policy & Regulation

Producers Sue Oregon Over ‘Crushing’ EPR Recycling Law, Call It Unconstitutional

 
• By Eileen Francis

A national wholesalers’ trade group is suing Oregon, claiming its EPR law, which requires producers to register, report packaging data and pay fees, is unconstitutional and overly burdensome.

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By Lauren Nardella

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.